retatrutide and blindness Ozempic In 2025: Essential Facts For Safe Decisions GLP 1 Blindness Risk |

It is not official but it is happening often In fact, I cannot see any scientific reason why GLP-1 based therapies could not be titrated similarly to insulin Advantages such as better tolerability or lower costs are there Perhaps time has come to discuss this with pharma (not only tirzepatide but also semaglutide and others) and test to make it official

It was approved by the FDA under the trade name Adlyxin in 2016 and launched in China in January 2018

Tirzepatide is a dual GLP-1/GIP agonist, already FDA- and EMA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound)

"2030, " 2 3

"Novo Nordisk A/S: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes" (Press release)

Tesamorelin provides the strongest evidence-based GHRH stimulation for VAT reduction